Unique ID issued by UMIN | UMIN000029088 |
---|---|
Receipt number | R000033268 |
Scientific Title | Effect of probiotics and/or synbiotics on intestinal environment in healthy adults. |
Date of disclosure of the study information | 2019/04/01 |
Last modified on | 2019/09/06 16:23:47 |
Effect of probiotics and/or synbiotics on intestinal environment in healthy adults.
Effect of probiotics and/or synbiotics on intestinal environment.
Effect of probiotics and/or synbiotics on intestinal environment in healthy adults.
Effect of probiotics and/or synbiotics on intestinal environment.
Japan |
Healthy adults
Adult |
Others
NO
To verify the effect of bifidobacterium and/or bifidobacterium with dietary fiber on intestinal environment.
Efficacy
Not applicable
16S rRNA gene based metagenome analysis of gut microbiome
Fecal short chain fatty acid concentration, fecal bifidobacteria, defecation frequency
Interventional
Parallel
Randomized
Individual
Double blind -all involved are blinded
Active
3
Prevention
Food |
Intake of drink containing high-dose bifidobacterium for 4 weeks - Washout 4 weeks.
Intake of drink containing low-dose bifidobacterium for 4 weeks - Washout 4 weeks.
Intake of drink containing bifidobacterium with dietary fiber for 4 weeks - Washout 4 weeks.
20 | years-old | <= |
65 | years-old | >= |
Male and Female
Subjects whose defecation frequency is more than five times per week.
1. Subjects regularly use intestinal drugs and laxatives (including strong laxatives).
2. Subjects habitually consume higher amount of alcohol.
3. Subjects who can't stop intake food containing bifidobacteria, and/or enhanced with oligosaccharide, dietary fiber during this study.
4. Subjects who have serious diseases requiring an urgent treatment, or who accept severe complication.
5. Subjects who have a medical history of diseases or surgeries affecting digestion, absorption and bowel movement.
6. Subjects who have allergy to test food.
7. Subjects who is pregnant or willing to be pregnant or breast-feeding during this study.
8. Subjects who are participated in other clinical trials that intake/apply any of food, drug, and cosmetics.
45
1st name | Takashi |
Middle name | |
Last name | Mawatari |
Ezaki Glico Co., Ltd
Institute of health science
555-8502
4-6-5 Utajima Nishiyodogawa-ku Osaka, 555-8502, Japan
0664778425
takashi.mawatari@glico.com
1st name | Takashi |
Middle name | |
Last name | Mawatari |
Ezaki Glico Co., Ltd
Institute of health sciences
555-8502
4-6-5 Utajima Nishiyodogawa-ku Osaka, 555-8502, Japan
0664778425
takashi.mawatari@glico.com
Ezaki Glico Co., Ltd
Ezaki Glico Co., Ltd
Self funding
The Institutional Review Board of Glico Group
2-4, Komatsubara-cho, Kita-ku, Osaka, Japan
+81-6-6477-8201
ebisutani-kazuki@glico.co.jp
NO
2019 | Year | 04 | Month | 01 | Day |
Unpublished
63
1. The intestinal microbiota is modulated.
2. The Faecalibacterium ratio, Bifidobacterium ratio and number, as well as the amount of short-chain fatty acid in feces increase.
3. The effect on intestinal microbiota varies depending on the number of ingested bacteria.
2019 | Year | 09 | Month | 06 | Day |
Completed
2017 | Year | 09 | Month | 04 | Day |
2017 | Year | 09 | Month | 04 | Day |
2017 | Year | 09 | Month | 11 | Day |
2017 | Year | 12 | Month | 08 | Day |
2019 | Year | 03 | Month | 04 | Day |
2019 | Year | 03 | Month | 06 | Day |
2019 | Year | 03 | Month | 31 | Day |
The group of interventions control 3 was excluded from analysis due to defect of the test drink.
2017 | Year | 09 | Month | 11 | Day |
2019 | Year | 09 | Month | 06 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000033268